BC Week In Review | Jul 19, 2004
Company News

curasan AG, Ascension Orthopedics Inc. sales and marketing update

Ascension received an exclusive license to distribute in the U.S. CUR's Cerasorb Ortho granules and block forms for applications in orthopedics, with the exception of the spine market. Under a 2003 deal, CryoLife Inc. (CRY,...
BC Week In Review | Apr 5, 2004
Clinical News

Cerasorb M Ortho regulatory update

The FDA granted 510(k) marketing clearance for synthetic bone regeneration material Cerasorb M Ortho for use in orthopedics and trauma. The product is an improved formulation of the company's approved Cerasorb Ortho. CUR said the...
BC Week In Review | Jan 19, 2004
Clinical News

Cerasorb Dental regulatory update

The FDA approved CUR's PMA for Cerasorb Dental resorbable tricalcium phosphate ceramic as a bone regeneration material for the dental sector. Cerasorb already has marketing clearance in the areas of orthopedics and veterinary medicine. CUR...
BC Week In Review | Jun 23, 2003
Company News

curasan AG, New Generation Devices sales and marketing update

New Generation will distribute in the U.S. curasan's Cerasorb VET resorbable tricalcium phosphate ceramic for use as a bone regeneration material. U.S. launch is expected within the next three months. curasan AG (FSE:CUR), Kleinostheim, Germany...
BC Week In Review | Feb 10, 2003
Company News

curasan AG, CryoLife sales and marketing update

CRY received exclusive U.S. distribution rights to CUR's Cerasorb Ortho resorbable bone graft substitute for orthopedic indications. The deal excludes spine and dental applications. CRY also launched the product. curasan AG (NMarkt:CUR), Kleinostheim, Germany  ...
BioCentury | Feb 10, 2003
Finance

Ebb & Flow

Even though Scios and Johnson & Johnson were mum Friday over JNJ's rumored move to acquire SCIO, investors won't have to wait long for the biotech company to end its silence, as SCIO's fourth quarter...
BioCentury | Jul 16, 2001
Finance

Ebb & Flow

In its early years, the biotech sector would rise or fall on news from a single bellwether. But over the past decade, investors have become more sophisticated and understand that news from one company is...
BC Week In Review | Jul 9, 2001
Company News

curasan AG sales and marketing update

CUR launched in Europe its Cerasorb resorbable tricalcium phosphate ceramic for use as a bone regeneration material in the entire skeletal system. Prior, CUR said the product was used in dentistry and maxillofacial surgery. curasan...
BioCentury | Jul 9, 2001
Finance

Ebb & Flow

If summer is the time for fishing, biotech investors will be encouraged to find more big-game fish in the larger tide pools: Between Dec. 31, 1999 and last Friday, the number of companies valued above...
BC Extra | Jul 5, 2001
Company News

curasan jumps on Cerasorb news

curasan (NMarkt:CUR) was up EUR2.40 (49%) to EUR7.30 ($6.21) on Thursday, following the European launch of its Cerasorb, a resorbable tricalcium phosphate ceramic, for use as a bone regeneration material in the entire skeletal system....
Items per page:
1 - 10 of 10